INCREASING MEDICAL MARIJUANA AND CANNABIDIOL RESEARCH

The order directs federal agencies to increase research into medical marijuana and cannabidiol (CBD). It highlights the Food and Drug Administration's (FDA) support for marijuana's use in treating certain medical conditions and the Department of Health and Human Services' (HHS) recommendation to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). The order also points to the potential of hemp-derived cannabinoids to improve patient symptoms and calls for enhanced research infrastructure to better inform doctors and patients about marijuana and CBD use.